Illumina (NASDAQ:ILMN) Downgraded by Barclays to "Underweight"

Barclays cut shares of Illumina (NASDAQ:ILMN - Free Report) from an equal weight rating to an underweight rating in a report published on Monday morning, Marketbeat Ratings reports. Barclays currently has $100.00 target price on the life sciences company's stock, down from their prior target price of $130.00.

Several other analysts have also issued reports on the stock. UBS Group boosted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Leerink Partners raised their target price on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Finally, Hsbc Global Res raised shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Moderate Buy" and an average price target of $159.45.

Illumina Price Performance

ILMN traded down $2.84 during trading on Monday, reaching $102.15. The stock had a trading volume of 2,039,623 shares, compared to its average volume of 2,222,310. The stock has a market cap of $16.20 billion, a PE ratio of -13.29 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina has a one year low of $100.08 and a one year high of $156.66. The business has a 50-day moving average of $135.90 and a 200-day moving average of $135.48.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, equities research analysts anticipate that Illumina will post 4.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sei Investments Co. boosted its holdings in shares of Illumina by 3.6% during the fourth quarter. Sei Investments Co. now owns 134,913 shares of the life sciences company's stock valued at $18,028,000 after acquiring an additional 4,738 shares during the period. American Century Companies Inc. boosted its stake in Illumina by 11.5% during the 4th quarter. American Century Companies Inc. now owns 226,852 shares of the life sciences company's stock valued at $30,314,000 after purchasing an additional 23,338 shares during the period. Virtu Financial LLC bought a new position in Illumina in the 4th quarter worth about $1,173,000. Lee Danner & Bass Inc. acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $48,000. Finally, Magnetar Financial LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $2,931,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.